Related Experiment Video
Updated: May 22, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published on: November 10, 2023
[Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)]
Kisato Nosaka1, Tatsuya Kawaguchi
1Cancer Center, Kumamoto University Hospital.
Abstract:
Hematopoietic malignancies, including leukemia, lymphoma and multiple myeloma, are classified and predicted a prognosis by morphologic, cytogenetic and molecular features. With advances in molecular targeted therapy and hematopoietic stem cell transplantation, monitoring of minimal residual disease (MRD) is required for evaluation of an optimal response to therapy and early detection of disease relapse. Analysis of immunophenotypes and chimeric fusion genes characteristic for hematopoietic malignant cells are clinically useful biomarkers to classify into subtype at diagnosis and monitor MRD. On the other hand, serum markers reflecting tumor burden are clinically useful to monitor the disease progression in hematopoietic malignancies: e.g., LDH and soluble IL-2 receptor for lymphoma; M-protein and free light chain for multiple myeloma.
Related Concept Videos
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Regulation of Hematopoietic Stem Cells
